DDInter802 DDInter927
Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as _Galanthus nivalis_. Galantamine was first studied in paralytic and neuropathic conditions, such as myopathies and postpolio paralytic conditions, and for reversal of neuromuscular blockade.[A182993,A201968] Following the discovery of its AChE-inhibiting properties, the cognitive effects of galantamine were studied in a wide variety of psychiatric disorders such as mild cognitive impairment, cognitive impairment in schizophrenia and bipolar disorder, and autism; however, re-development of the drug for Alzheimer’s disease did not commence until the early 1990s due to difficulties in extraction and
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Galantamine {u} (Compound) resembles {v} (Compound) Dihydrocodeine
Galantamine {u} (Compound) resembles {v} (Compound) Codeine
Galantamine {u} (Compound) treats {v} (Disease) Alzheimer's disease
Galantamine {u} (Compound) binds {v} (Gene) CHRND
Galantamine {u} (Compound) upregulates {v} (Gene) HERC6
Galantamine {u} (Compound) downregulates {v} (Gene) MBOAT7
Galantamine {u} (Compound) causes {v} (Side Effect) Hypotension
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hyoscyamine
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyclizine
Galantamine {u} may lead to a major life threatening interaction when taken with {v} Bupropion
Galantamine (Compound) resembles Dihydrocodeine (Compound)
Galantamine (Compound) resembles Codeine (Compound)
Galantamine (Compound) treats Alzheimer's disease (Disease)
Galantamine (Compound) binds CHRND (Gene)
Galantamine (Compound) upregulates HERC6 (Gene)
Galantamine (Compound) downregulates MBOAT7 (Gene)
Galantamine (Compound) causes Hypotension (Side Effect)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Galantamine may lead to a major life threatening interaction when taken with Bupropion